Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.

Nguyen K, Jack K, Sun W.

Diseases. 2015 Dec 25;4(1). pii: E1. doi: 10.3390/diseases4010001. Review.

2.

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.

Patt Y, Rojas-Hernandez C, Fekrazad HM, Bansal P, Lee FC.

Oncologist. 2017 Oct;22(10):1158-e116. doi: 10.1634/theoncologist.2017-0168. Epub 2017 Jul 7.

3.

Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors.

Mahfouz N, Tahtouh R, Alaaeddine N, El Hajj J, Sarkis R, Hachem R, Raad I, Hilal G.

PLoS One. 2017 Jun 8;12(6):e0179202. doi: 10.1371/journal.pone.0179202. eCollection 2017.

4.

The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.

Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1732-1741. doi: 10.1007/s00259-017-3724-2. Epub 2017 May 29.

5.

Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.

Kim DW, Talati C, Kim R.

J Gastrointest Oncol. 2017 Apr;8(2):256-265. doi: 10.21037/jgo.2016.09.07. Review.

6.

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.

Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Furuta M, Tsunoda T, Miyano S, Kubo M, Aikata H, Ochi H, Kawakami YI, Arihiro K, Ohdan H, Nakagawa H, Chayama K.

Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534. doi: 10.1016/j.jcmgh.2015.06.009. eCollection 2015 Sep.

7.

Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma.

Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R.

Front Pharmacol. 2016 Nov 9;7:428. eCollection 2016. Review.

8.

Challenges of advanced hepatocellular carcinoma.

Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F.

World J Gastroenterol. 2016 Sep 14;22(34):7645-59. doi: 10.3748/wjg.v22.i34.7645. Review.

9.

Combination treatment including targeted therapy for advanced hepatocellular carcinoma.

Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H.

Oncotarget. 2016 Oct 25;7(43):71036-71051. doi: 10.18632/oncotarget.11954. Review.

10.

Mixed response and time-to-event endpoints for multistage single-arm phase II design.

Lai X, Zee BC.

Trials. 2015 Jun 4;16:250. doi: 10.1186/s13063-015-0743-9.

11.

Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.

Deng GL, Zeng S, Shen H.

World J Hepatol. 2015 Apr 18;7(5):787-98. doi: 10.4254/wjh.v7.i5.787. Review.

12.

Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.

Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ.

World J Gastroenterol. 2014 Aug 14;20(30):10249-61. doi: 10.3748/wjg.v20.i30.10249. Review.

13.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.

Ikeda M, Shiina S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Ueno H, Morizane C, Kondo S, Sakamoto Y, Asaoka Y, Tateishi R, Koike K, Arioka H, Okusaka T.

Invest New Drugs. 2014 Oct;32(5):928-36. doi: 10.1007/s10637-014-0109-2. Epub 2014 May 15.

14.

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

Welker MW, Trojan J.

Cancer Manag Res. 2013 Oct 8;5:337-47. doi: 10.2147/CMAR.S35029. Review.

15.

Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Shao YY, Hsu CH, Cheng AL.

Liver Cancer. 2013 Apr;2(2):93-107. doi: 10.1159/000343845. Review.

16.

Molecular targeted therapy for hepatocellular carcinoma: current and future.

Shin JW, Chung YH.

World J Gastroenterol. 2013 Oct 7;19(37):6144-55. doi: 10.3748/wjg.v19.i37.6144. Review.

17.

Targeted therapies in the treatment of advanced hepatocellular carcinoma.

Wei Z, Doria C, Liu Y.

Clin Med Insights Oncol. 2013 May 20;7:87-102. doi: 10.4137/CMO.S7633. Print 2013.

18.

Antiangiogenic therapies for advanced hepatocellular carcinoma.

Sampat KR, O'Neil B.

Oncologist. 2013;18(4):430-8. doi: 10.1634/theoncologist.2012-0388. Epub 2013 Apr 10. Review.

19.

Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.

Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC.

PLoS One. 2012;7(12):e49717. doi: 10.1371/journal.pone.0049717. Epub 2012 Dec 19. Review.

20.

Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.

Duffy A, Wilkerson J, Greten TF.

Hepatology. 2013 Mar;57(3):1068-77. doi: 10.1002/hep.26120. Epub 2013 Jan 18. Review.

Supplemental Content

Support Center